

Supplemental Material

Literatur

- Ostrom QT, Cioffi G, Gittleman H et al: CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. *Neuro-Oncology* 2019;21(5 Suppl):v1–v100.
- Louis DN, Perry A, Reifenberger G et al: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta neuropathologica* 2016;131(6):803–820.
- Melean G, Sestini R, Ammannati F, Papi A: Genetic Insights into Familial Tumors of the Nervous System. *American Journal of Medical Genetics* 2004;129C:74–84.
- Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I: Long-term Follow-Up for Brain Tumor Development After Childhood Exposure to Ionizing Radiation for Tinea Capitis. *Radiat Res.* 2005;163:424–32.
- Bondy ML, Scheurer ME, Malmer B et al: Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. *Cancer* 2008;113(7 Suppl):1953–68.
- Deutsche Gesellschaft für Neurologie. Gliome - Leitlinien für Diagnostik und Therapie in der Neurologie. S2k-Leitlinie;2015. Im Internet: <https://www.awmf.org/leitlinien/detail/II/030-099.html> (letzter Aufruf 03.01.2020).
- Roth P, Hottinger AF, Hundsberger T et al: A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. *Swiss Med Wkly.* 2020;150:w20256.
- Upadhyay N, Waldman AD: Conventional MRI Evaluation of Gliomas. *Br J Radiol* 2011;84:S107–11.
- Chiavazza C, Pellerino A, Ferrio F, Cistaro A, Soffietti R, Rudà R: Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring. *Biomed Res Int* 2018;2018:3606970.
- Wen PY, Macdonald DR, Reardon DA et al: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol.* 2010;28:1963–72.
- Ertl-Wagner B, Ingrisch M, Niyazi M et al: PET-MR bei Patienten mit Glioblastoma multiforme. *Der Radiologe* 2013;53(8):682–690.
- Hartmann C, Hentschel B, Wick W, et al: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. *Acta Neuropathol* 2010;120:707–718.
- Brat DJ, Aldape K, Colman H et al: cIMPACT-NOW update 3: recommended diagnostic criteria for „Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV“. *Acta Neuropathol.* 2018;136(5):805–810.
- Weller M, Stupp R, Reifenberger G et al: MGMT promoter methylation in malignant gliomas: ready for personalized medicine? *Nat Rev Neurol.* 2010;6(1):39–51.
- Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE: Extent of Resection of Glioblastoma Revisited: Personalized Survival Modeling Facilitates More Accurate Survival Prediction and Supports a Maximum-Safe-Resection Approach to Surgery. *J Clin Oncol.* 2014; 32(8): 774–782.
- Stupp R, Mason WP, van den Bent MJ: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *The New England Journal of Medicine* 2005;352(10):987–996.
- Skardelly M, Dangel E, Gohde J et al: Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma. *Oncologist.* 2017;22(5):570–575.
- Karnofsky DA, Burchenal JH: The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: CM MacLeod (Hrsg.): *Evaluation of Chemotherapeutic Agents.* Columbia Univ Press, 1949, S. 196.
- Nayak L, DeAngelis LM, Brandes AA et al: The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. *Neuro-Oncology* 2017;19:625–635.
- Perry JR, Laperriere N, O'Callaghan CJ et al: Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. *N Engl J Med* 2017;376:1027–37.
- Wick A, Kessler T, Platten M et al: Superiority of Temozolomide Over Radiotherapy for Elderly Patients With RTK II Methylation Class, MGMT Promoter-Methylated Malignant Astrocytoma. *Neuro Oncol* 2020;noaa033. Online ahead of print.
- Herrlinger U, Tzaridis T, Mack F et al: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. *Lancet.* 2019;393(10172):678–688.
- Brandesma D, Stalpers L, Taal W, Sminia P, van den Bent MJ: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. *Lancet Oncol.* 2008;9(5):453–61.
- Wick W, Platten M, Meisner C, et al., for the Neurooncology Working Group (NOA) of the German Cancer Society: Chemotherapy versus radiotherapy for malignant astrocytoma in the elderly. *Lancet Oncol* 2012;13:707–715.
- Weller M, van den Bent M, Tonn JC et al: European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. *Lancet Oncol* 2017; 18: e315–29.
- Wick W, Osswald M, Wick A, Winkler F: Treatment of glioblastoma in adults. *Ther Adv Neurol Disord.* 2018;11:1756286418790452.
- Weller M, Le Rhun E, Preusser M, Tonn JC, Roth P: How we treat glioblastoma. *ESMO Open* 2019;4:e000520.
- Seystahl K, Hentschel B, Loew S et al: Bevacizumab Versus Alkylating Chemotherapy in Recurrent Glioblastoma. *J Cancer Res Clin Oncol* 2020;146:659–670.
- Kirson ED, Dbaly V, Tovarys F et al: Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. *PNAS* 2007;104(24): 10152–10157.
- Stupp R, Taillibert S, Kanner A et al: Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. *JAMA.* 2017;318(23):2306–2316.
- Deutsche Krebsgesellschaft. Supportive Therapie bei onkologischen PatientInnen - interdisziplinäre Querschnittsleitlinie. S3-Leitlinie;2019. Im Internet: <https://www.awmf.org/leitlinien/detail/II/032-054OL.html> (letzter Aufruf 03.01.2020).
- Pace A, Dirven L, Koekkoek JAF et al: European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. *Lancet Oncol* 2017; 18: e330–40.
- Jessurun CAC, Hulsbergen AFC, Cho LD, Aglio LS, Nandoe Tewarie RDS, Broekman MLD: Evidence-based dexamethasone dosing in malignant brain tumors: what do we really know? *Journal of Neuro-Oncology* 2019;144(2):249–264.
- Lee EQ, Wen PY: Corticosteroids for peritumoral edema: time to overcome our addiction? *Neuro-Oncology* 2016;18(9):1191–1192.
- Pitter KL, Tamagno I, Alikhanian K et al: Corticosteroids compromise survival in glioblastoma. *Brain.* 2016;139(Pt 5):1458–71.
- Kirste S, Treier M, Wehrle SJ et al: Boswellia Serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors: A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial. *Cancer* 2011;117:3788–95.
- Lange F, Weßlau K, Porath K et al: AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. *PLoS One.* 2019;14(2):e0211644.
- Ford E, Catt S, Chalmers A, Fallowfield L: Systematic review of supportive care needs in patients with primary malignant brain tumors. *Neuro-oncology* 2012;14:392–404.
- Reijneveld JC, Armstrong T.: *Psycho-oncology.* Handb Clin Neurol 2016;134:305–13.
- P. Herschbach, J. Weis (Hrsg.): Screeningverfahren in der Psychoonkologie. Testinstrumente zur Identifikation betreuungsbedürftiger Krebspatienten. Eine Empfehlung der PSO für die psychoonkologische Behandlungspraxis. Im Internet: https://www.dapo-ev.de/wp-content/uploads/2017/04/psa_broschuere2.pdf. Zuletzt abgerufen 02.07.2020, 15.40 Uhr.
- Rosenberger C, Hocker A, Cartus M et al: Outpatient psycho-oncological care for family members and patients: access, psychological distress and supportive care needs. *Psychother Psychosom Med Psychol* 2012;62:185–194.
- Gehring K, Aaronson NK, Gundy CM, et al: Predictors of neuropsychological improvement following cognitive rehabilitation in patients with gliomas. *J Int Neuropsychol Soc* 2011;17:256–266.
- Coomans MB et al: Treatment of Cognitive Deficits in Brain Tumour Patients: Current Status and Future Directions. *Curr Opin Oncol* 2019;31:540–547.
- Gately L, McLachlan SA, Dowling A, Philip J: Life beyond a diagnosis of glioblastoma: a systematic review of the literature. *J Cancer Surviv* 2017;11:447–452.
- Koekkoek JAF, Dirven L, Sizoo EM et al: Symptoms and medication management in the end of life phase of high-grade glioma patients. *J Neurooncol.* 2014;120:589–95.